Back to results
US 2023/0399399 A1Published application
Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof
AssigneeMacroGenics, Inc.
InventorsLeslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
Life of this patent
Estimating the term…
Abstract
CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.
Claims17
1-17. (canceled)
A method of treating a hematologic malignancy associated in a subject in need thereof, said method comprising administering to said subject a covalently associated polypeptide complex, wherein said polypeptide complex comprises a first polypeptide chain and a second polypeptide chain, wherein:
- a) said first polypeptide chain comprises a polypeptide having the amino acid sequence of SEQ ID NO:2 linked to a charged helical domain having the amino acid sequence of SEQ ID NO:12;
- and
- b) said second polypeptide chain comprises a polypeptide having the amino acid sequence of SEQ ID NO:2 linked to a charged helical domain having the amino acid sequence of SEQ ID NO:13;
- wherein said charged helical domain of said first polypeptide chain and said charged helical domain of said second polypeptide chain are covalently bonded to one another via a disulfide bond.
1 more element
Dependencies are inferred from the claim text.